普拉克索联合复方左旋多巴对帕金森病患者运动功能及非运动症状的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Pramipexole combined with Compoud Levodopa on motor function and non-motor symptoms in patients with Parkinson′s disease (PD). Methods A total of 96 patients with PD admitted to the Third People′s Hospital of Dalian from June 2017 to May 2019 were selected as the research objects, they were divided into observation group and control group according to the random number table method, with 48 cases in each group. The control group received Compound Levodopa, the observation group received Compound Levodopa combined with Pramipexole, both for 16 weeks. The united Parkinson′s disease scale (UPDRS) Ⅲ, hamilton depression scale(HAMD), non motor symptoms and the total incidence of adverse reactions were compared between the two groups. Results Before treatment, there were no significant differences in UPDRSⅢ, HAMD scores, frequency of urination, urgency of urination, abnormal sensation, sleep disorder, salivation and constipation between the two groups (P＞0.05). After treatment, the scores of UPDRSⅢ, HAMD, frequency of urination, urgency of urination, abnormal sensation and sleep disorder in the observation group were lower than those in the control group, the differences were statistically significant (P＜0.05). The total incidence of adverse reactions in the observation group was 6.25%, which was lower than 20.83% in the control group, the difference was statistically significant (P＜0.05). Conclusion Pramipexole combined with Compound Levodopa can relieve anxiety of PD patients, reduce the incidence of non motor symptoms and adverse reactions, which is worthy of clinical application.

Key words： Parkinson′s disease Pramipexole Compound levodopa Motor function Non-motor symptoms

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I6/69

[1]	张建勋，高秀先，万和斌，等.帕金森综合征患者非运动症状发生特点、影响因素及对生活质量的影响[J].广东医学，2019，40（15）：2179-2183.
[2]	杨俊秀，张本恕，国树超，等.帕金森病与特发性震颤患者非运动症状的临床分析[J].中国综合临床，2018，34（1）：38-41.
[3]	韦慧君，杜孟，白宏英.血清褪黑素、谷胱甘肽与帕金森氧化应激的相关性[J].中国医学科学院学报，2019，41（2）：183-187.
[4]	何剑波，李会琪，翟洁敏，等.复方左旋多巴制剂与帕金森病患者同型半胱氨水平及认知损害的相关性分析[J].陕西医学杂志，2017，46（2）：250-252.
[5]	田永青，霍秀利，霍金莲，等.普拉克索对帕金森合并抑郁患者疗效的影响[J].检验医学与临床，2019，16（20）：3021-3023.
[6]	王妍，张孝良，马正磊.普拉克索治疗帕金森病患者左旋多巴诱导的运动障碍的疗效[J].徐州医学院学报，2016，36（9）：582-584.
[7]	中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南（第三版）[J].中华神经科杂志，2014，47（6）：428-433.
[8]	卢靖，朱余兵，潘希丁.2015-2017年南京市第一医院抗帕金森病药物的使用情况分析[J].现代药物与临床，2019，34（9）：2817-2821.
[9]	李迎，刘婷婷，胡盼盼，等.多巴胺能药物对早期帕金森病患者决策认知功能的影响[J].临床神经病学杂志，2019，32（3）：206-209.
[10]	赵玉燕，山媛.美多巴联合普拉克索治疗对帕金森患者运功功能的影响及安全性分析[J].广西医科大学学报，2019，36（6）：1002-1005.
[11]	徐巍.补肾复方联合美多芭治疗早中期帕金森病的研究[J].现代中西医结合杂志，2016，25（6）：604-606，651.
[12]	沈骏，侍永伟，鞠强国，等.渐进性抗阻训练联合普拉克索治疗改善帕金森病患者肌张力[J].神经损伤与功能重建，2019，14（3）：124-127.
[13]	朱华伟，齐进兴，邓建中.普拉克索治疗帕金森病伴抑郁的临床效果[J].中国实用神经疾病杂志，2016，19（22）：115-116.
[14]	宋征宇，岳秉宏，谷伟.负性生活事件对帕金森病非运动症状的影响[J].中西医结合心脑血管病杂志，2017，15（17）：2187-2189.
[15]	陈敏.美多芭联合盐酸普拉克索治疗帕金森病非运动症状的临床效果[J].广西医学，2019，41（14）：1784-1786，1791.